

I. Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1-12. (Canceled)

13. (Previously Presented) A pharmaceutical dosage form comprising an immediate release and a controlled release component, wherein said immediate release component comprises a GABA_B agonist and a pharmaceutically acceptable excipient, and said controlled release component consisting essentially of ~~comprises~~ a GABA_B agonist and a controlled release material selected from the group consisting of an acrylic polymer, an alkylcellulose, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, a hydroxyalkylcellulose, and a combination thereof; wherein said immediate release component exhibits an in vitro dissolution profile comprising at least about 80% GABA_B agonist release after 1 hour in simulated gastric fluid; wherein said controlled release component exhibits an in vitro dissolution profile in simulated gastric fluid/simulated intestinal fluid (1 hour switchover) medium comprising from about 2% to about 90% GABA_B agonist release after 1 hour, at least about 30% GABA_B agonist release after 4 hours, and at least about 40% GABA_B agonist release after 6 hours; wherein the dosage form releases at least 25% GABA_B agonist in the intestinal tract; and wherein the ratio of said immediate release component to said controlled release component is from about 1:10 to about 10:1.

14. (Original) A pharmaceutical dosage form according to claim 13 wherein said ratio of immediate release component to controlled release component is from about 1:4 to about 4:1.

15. (Original) A pharmaceutical dosage form according to claim 13 wherein said ratio of immediate release component to controlled release component is from about 1:2 to about 1:1.

16. (Original) A pharmaceutical dosage form according to claim 13 wherein said GABA_B agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

17. (Original) A pharmaceutical dosage form according to claim 16 wherein said baclofen is a racemic mixture.

18. (Withdrawn) A pharmaceutical dosage form according to claim 16 wherein said baclofen consists essentially of the L-baclofen enantiomer.

19. (Withdrawn) A pharmaceutical dosage form according to claim 16 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

20. (Original) A pharmaceutical dosage form according to claim 16 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

21. (Original) A pharmaceutical dosage form according to claim 16 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

22. (Withdrawn) A pharmaceutical dosage form according to claim 13 wherein said dosage form is a tablet.

23. (Original) A pharmaceutical dosage form according to claim 13 wherein said dosage form is a capsule.

24. (Original) A pharmaceutical dosage form according to claim 23 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

Appl. Serial No. 10/815,926
Response dated July 29, 2008
Reply to Final Office Action dated May 29, 2008

25-56. (Canceled)

57. (Previously Presented) A pharmaceutical dosage form according to claim 23, wherein the dosage form does not include an additional active agent.